Research Paper Volume 15, Issue 22 pp 13265—13286
Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients
Figure 7. KLRB1 overexpression was correlated with the OS in cancer patients on immunotherapy. (A) Anti-PD-1; (B) Pembrolizumab; (C) Anti-PD-L1; (D) Atezolizumab; (E) Ipilimumab; (F) Pretreatment; (G) Ontreatment. Abbreviation: OS: overall survival.